Stockscreener 앱 받기
35.42
0.77%
0.27
시간 외 거래:
36.12
0.70
+1.98%
전일 마감가:
$35.15
열려 있는:
$35.1
하루 거래량:
4.00M
Relative Volume:
1.12
시가총액:
$15.31B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
15.40
EPS:
2.3
순현금흐름:
$827.02M
1주 성능:
-2.96%
1개월 성능:
-2.56%
6개월 성능:
+8.09%
1년 성능:
+25.34%
1일 변동 폭
$35.05
$35.65
1주일 범위
$34.84
$36.94
52주 변동 폭
$24.05
$38.00
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.42 | 15.20B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma Completes $2 Billion Senior Notes Offering - TipRanks
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
Gainers Report: Will Royalty Pharma plc outperform the market in YEARMarket Sentiment Summary & Stock Timing and Entry Methods - خودرو بانک
Royalty Pharma stock price target raised to $38 from $37 at UBS - Investing.com UK
Royalty Pharma (RPRX) PT Raised to $38 at UBS, But Firm on Sidelines Due to Structural Issues - StreetInsider
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts - Yahoo Finance
Royalty Pharma Plc's (NASDAQ:RPRX) Prospects Need A Boost To Lift Shares - 富途牛牛
Aug Chart Watch: Is Royalty Pharma plc stock technically oversoldTrade Risk Assessment & Community Verified Trade Alerts - خودرو بانک
Pacific Capital Partners Ltd Cuts Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Petrus Trust Company LTA Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Empowered Funds LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Signal Recap: Will Royalty Pharma plc be affected by tariffs2025 Earnings Surprises & AI Powered Market Entry Strategies - خودرو بانک
USS Investment Management Ltd Sells 42,500 Shares of Royalty Pharma PLC $RPRX - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Holdings in Royalty Pharma PLC $RPRX - MarketBeat
EP Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Uniplan Investment Counsel Inc. Purchases 11,904 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Stake Lessened by Baird Financial Group Inc. - MarketBeat
TD Cowen reiterates Buy rating on Royalty Pharma stock, citing strong metrics - Investing.com Nigeria
Royalty Pharma: Investor Day Upside (NASDAQ:RPRX) - Seeking Alpha
TD Cowen Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Alliancebernstein L.P. Purchases 86,873 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation - MarketScreener
Volatility clustering patterns for Royalty Pharma plcCEO Change & AI Enhanced Market Trend Forecasts - Newser
Why Royalty Pharma plc is moving todayMarket Risk Report & Smart Allocation Stock Tips - Newser
Punch & Associates Investment Management Inc. Purchases 101,390 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Transcript : Royalty Pharma plcAnalyst/Investor Day - MarketScreener
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program - Insider Monkey
Royalty Pharma prices $2B senior unsecured notes - MSN
Royalty Pharma Expects At Least Mid-teens Average Annual Total Shareholder Return Over 2025-2030. - Nasdaq
Royalty Pharma : Investor Day Presentation - MarketScreener
Royalty Pharma : Role of Royalties in Funding Biopharma Innovation - MarketScreener
Royalty Pharma targets mid-teens annual shareholder return over next 5 years - MarketScreener
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation - MarketScreener
$4.7 Billion Growth Target: Royalty Pharma Plans to Double Biopharma Funding as Market Expands Rapidly - Stock Titan
Royalty Pharma PLC $RPRX Stock Position Lifted by AQR Capital Management LLC - MarketBeat
Nomura Holdings Inc. Buys New Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma and Deloitte Release Landmark Report on Biopharma Royalty Market Insights and Trends - Quiver Quantitative
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market - MarketScreener
87% of Pharma Leaders Embrace Royalty Funding: Royalty Pharma's Groundbreaking Industry Study Reveals Shift - Stock Titan
Amundi Sells 1,316,620 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Acquires 56,419 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cutter Capital Management LP Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Panagora Asset Management Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma’s $2 Billion Debt Raise Could Be a Game Changer for RPRX - simplywall.st
Is Royalty Pharma plc likely to announce a buyback2025 Price Targets & AI Enhanced Trade Execution Alerts - 뉴스영
AlTi Global Inc. Lowers Holdings in Royalty Pharma PLC $RPRX - MarketBeat
What is the long term forecast for Royalty Pharma plc stock2025 Support & Resistance & AI Driven Price Forecasts - beatles.ru
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.91%
1.53%
자본화:
|
볼륨(24시간):